The Motley Fool
18 Oct 2026, 18:00 UTC · 3h ago
President Trump's Push to Reschedule Marijuana Hit a Snag. Is Green Thumb Still a Buy?
Impact · against what's priced in
The article is neutral to slightly negative as it confirms that regulatory hurdles are delaying the rescheduling of marijuana, which maintains the current tax burden on Green Thumb Industries. While the company's operational performance remains strong, these headwinds are widely anticipated and reflected in the current valuation.
- GTBIF−0.20
No priced-in read yet
- In context
Additional regulatory requests and a GAO report may delay the transition to Schedule III, prolonging the Section 280E tax burden that prevents the deduction of operating expenses. This offset is partially mitigated by a strong Q2 2026 normalized EBITDA of $84.3 million.
Read from the article alone
Top 1 mover · tap to explore
